8-K: Supernus Amends 2018 Merger Agreement Milestone Terms
Amendment to Merger Agreement
Supernus Pharmaceuticals, Inc. has amended its 2018 merger agreement with Reich Consulting Group, Inc. to adjust the timing and payment of certain milestones.
Summary
- Supernus Pharmaceuticals, Inc. (the Company) entered into a First Amendment to its Agreement and Plan of Merger dated September 12, 2018.
- The Amendment was made with Reich Consulting Group, Inc., acting as the Securityholder Representative.
- The purpose of the Amendment is to modify the timing and payment terms of specific milestones outlined in the original Merger Agreement.
- The Amendment was dated January 22, 2026, and reported on January 28, 2026.
- Certain confidential information within the Amendment has been omitted from public disclosure due to its immateriality and potential for competitive harm if revealed.
Sentiment
Score: 5
Explanation: The filing is purely administrative, detailing an amendment to an existing merger agreement's milestone terms. It contains no financial performance data, operational updates, or strategic shifts that would indicate a positive or negative sentiment.
Future Outlook
The filing does not provide any forward-looking statements or guidance beyond the administrative amendment of milestone terms.
Management Comments
- The report was signed by Timothy C. Dec, Senior Vice President and Chief Financial Officer of Supernus Pharmaceuticals, Inc.
Industry Context
This administrative filing reflects a routine adjustment to contractual terms within the pharmaceutical industry, specifically concerning a past merger agreement. It does not provide information directly related to broader industry trends or competitive positioning, but rather an internal operational adjustment to an existing deal.
Stakeholder Impact
- Shareholders: The amendment relates to milestone timing and payment, which could indirectly affect future cash flows or contingent liabilities related to the 2018 merger, though the filing states the omitted details are not material.
Key Dates
| Date | Description |
|---|---|
| September 12, 2018 | Original Agreement and Plan of Merger date |
| January 22, 2026 | Date of the First Amendment to Agreement and Plan of Merger |
| January 28, 2026 | Date of Report (earliest event reported) and filing date of the Form 8-K |
Keywords
Supernus Pharmaceuticals, Merger Agreement, Amendment, Milestones, Reich Consulting Group, SEC Filing, SUPN
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.